InMed Pharmaceuticals Inc (INM): It ain’t done yet

Play Episode

7min

Proactive - Interviews for investors

Tolu Minerals CEO reveals 8 new targets at Mt Pence and talks initial gold production at Tolukuma

Tolu Minerals Ltd CEO Iain Macpherson talked with Proactive about the company’s initial gold production at the Tolukuma Gold Mine in Papua New Guinea. While not commercial output yet, Macpherson explained that gold from commissioning demonstrates proof of concept and marks the start of larger-scale activity. The company is leveraging existing infrastructure valued at around AU$500 million, with a strategy focused on addressing previous cost pressures that led to mine closure. “The mine shut down, not because the resource ran out... but because they were faced with severe cost pressures,” Macpherson said, citing diesel dependence and lack of road access. Macpherson highlighted Tolu’s capital program and extensive exploration footprint across the broader Tolukuma structure. He detailed the utility of airborne magnetotelluric (MT) surveys, which provide deep, three-dimensional geophysical data. “It gives you a very good three-dimensional picture... and enhances target generation,” he said, noting this method’s success in similar geologies globally. The company also discussed its Mt Penck project on New Britain Island, revealing the identification of eight new porphyry targets based on the MT survey. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future content. #ToluMinerals #GoldMining #ASXTOK #PapuaNewGuinea #Tolukuma #GoldExploration #MiningStocks #PorphyryTargets #MTsurvey #JuniorMining #GoldProduction #InvestorUpdates #MiningNews

Proactive - Interviews for investors

BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

Frontier IP Group CEO on H1 highlights, €25m 2D Photonics funding round

Frontier IP Group PLC (AIM:FIPP) CEO Neil Crabb talked with Proactive's Stephen Gunnion about the company’s half-year results and how its portfolio has continued to attract investment and commercial traction despite difficult market conditions. Crabb highlighted a €25 million funding round for 2D Photonics (formerly CamGraphIC), backed by major names including Sony, Bosch, NATO’s Innovation Fund, and Italy’s CDP. The company is developing graphene-based technology to enhance silicon performance in data centres and potentially defence applications. He noted broader progress across the portfolio, including funding raised by DeakinBio for its novel materials, and commercial wins for Alusid, such as new floor tile launches with Topps Tiles. GraphEnergyTech has partnered with institutions in Taiwan on graphene electrode technology, a move Crabb described as “a really broad spectrum of interest.” Crabb also emphasised the importance of cost-efficiency alongside innovation, noting, “It's a cost that's at the heart of this.” Frontier IP looks for technologies that can deliver real-world economic benefits, from solar panel efficiency to energy-saving USB-C power tech by Pulsiv. He also pointed to companies like Cambridge Raman Imaging and Nandi Proteins as part of a portfolio seeing strong investor interest, with corporate VCs, public sector groups and angel networks all engaging. For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #FrontierIP #NeilCrabb #2DPhotonics #GrapheneTechnology #VentureCapital #DeepTech #CambridgeStartups #SustainableTech #GraphEnergyTech #AIMstocks #GreenInvesting #Semiconductors #InnovationFunding #TechInvestment #EnergyEfficiency

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Followers	190
Posts	15135
Boards Moderated	0
Alias Born	08/26/2010

Volume:	100,163
Day Range:	2.0001 - 2.38
Bid:	2.18
Ask:	2.29
Last Trade Time:	4:22:46 PM EDT
Total Trades:	524

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

INM Detailed Quote

Recent INM News

More INM News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent INM News

Go Ad-Free